+44 (0) 115 787 0500

Congratulations to Cara Therapeutics and Vifor Pharma on the FDA approval of Korsuva

DevelRx were privileged to support the registration of Korsuva for the relentless itch of pruritus suffered by chronic kidney disease patients on haemodialysis.

Korsuva (difelikefalin) is an injectable kappa opioid receptor agonist that targets the body's peripheral nervous system and offers significant improvements in safety and effectiveness on the current variety of antihistamine treatments used to combat pruritus.

Moderate to severe levels of pruritus affects roughly 40% of the 500,000 chronic kidney disease patients on haemodialysis in the USA. Korsuva will make a significant contribution to reducing the burden of disease in these patients.